Two Pore Guys to Present at Point-of-Care Diagnostics Symposium
Complete the form below to unlock access to ALL audio articles.
Two Pore Guys, Inc., (2PG) will showcase its sample-in/results-out molecular diagnostic platform at the Point-of-Care Diagnostics symposium, part of the Molecular Medicine Tri-Conference in San Francisco, on February 23rd at the Moscone South Convention Center.
The symposium is comprised of both developers and end-users of point of care (PoC) technologies, who will examine barriers to entry and proposed solutions for this critical marketplace. CEO Dan Heller and CSO Trevor Morin will discuss and demonstrate 2PG’s technology in a presentation titled, “Handheld, Single Molecule Sensitive Diagnostic Platform,” taking place from 12:40-1:15 p.m. PT in room 305.
Multiple barriers to entry have historically limited the commercial success of PoC diagnostics, such as rapid turnaround time, off-grid power sources, clinical sensitivity, and a broad menu of diagnostic tests. 2PG’s battery operated, hand-held device has single-molecule sensitivity and can measure targets ranging from small molecules and proteins, to DNA or RNA, including the presence of specific genes and mutations from bacteria, viruses, people, animals, and any other life form. The company’s novel business model allows third-parties to develop assays for its platform. Large diagnostic companies can even adapt reagents already used in reference lab systems, allowing for a broad menu of tests to be available for a PoC market.
Heller commented: “Molecular diagnostics is the gold standard for confirmatory diagnosis of infectious diseases, cancer, and other critical conditions, but providing PoC technologies that satisfy clinical sensitivity levels and can also be used outside of labs at very low price points has been challenging. Until now, no PoC solution has achieved single-molecule sensitivity at a price point that can attain broad market adoption, while also addressing multiple barriers to entry. We believe our solution for the PoC market will open many exciting opportunities for developers and end-users alike.”
2PG first formally introduced its platform last month when it announced a collaboration with UCSF to use its hand-held device to detect cell-free tumor DNA from blood and urine samples from cancer patients. The company also presented its platform in January at both the BioWeekSF series of conferences and at the Precision Medicine World Conference in Silicon Valley, where it won the prestigious “Most Promising Company” award.
